# Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

Source: https://onco.cc/trials/nct05308264/  
OnCo record `nct05308264` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of R906289 Monosodium (R289 Na) in myelodysplastic syndromes / neoplasms, run by Rigel Pharmaceuticals, now recruiting.

## Summary

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) is a phase 1/2 interventional study registered as NCT05308264 by Rigel Pharmaceuticals, with 86 participants planned, started 2022-09-12 and due to reach its primary completion in 2026-08. Interventions recorded: R906289 Monosodium (R289 Na).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05308264
- Phase: 1/2
- Setting: An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Relapsed/Refractory/Resistant to Prior Therapies
- Sponsor: Rigel Pharmaceuticals
- Enrolled: 86

## Sources

- ClinicalTrials.gov NCT05308264: https://clinicaltrials.gov/study/NCT05308264

## Connected records

- cancers: [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- companies: [Rigel Pharmaceuticals](https://onco.cc/companies/rigel-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct05308264.json